PROM1 and exocrine pancreatic carcinoma: Besides the application of CD133-targeted CAR T-cells in MLL leukemia [120], anti-CD133 CAR T-cells have been reported in a phase I trial including 14 patients with hepatocellular carcinoma (HCC), 7 patients with pancreatic carcinomas, and 2 patients with colorectal cancer [121].